(Q33700104)

28 July 2017

1 reference

title

Can pharmacokinetic monitoring improve clinical use of fluorouracil? (English)

1 reference

28 July 2017

1 reference

Young AM

1

1 reference

28 July 2017

Daryanani S

series ordinal

2

1 reference

28 July 2017

Kerr DJ

series ordinal

3

1 reference

28 July 2017

publication date

1 June 1999

1 reference

Clinical Pharmacokinetics

28 July 2017

published in

1 reference

28 July 2017

volume

36

1 reference

28 July 2017

issue

6

1 reference

28 July 2017

page(s)

391-398

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-199936060-00001

28 July 2017

exact match

0 references

cites work

No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion

1 reference

12 December 2020

Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial

1 reference

12 December 2020

Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance

1 reference

12 December 2020

Clinical pharmacology of 5-fluorouracil

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases

1 reference

12 December 2020

DoseVersus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU

1 reference

12 December 2020

Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.

1 reference

12 December 2020

Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule

1 reference

12 December 2020

Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy

1 reference

12 December 2020

Pharmacokinetics of 5-fluorouracil after short systemic infusion: plasma level at the end of the distribution phase as an indicator of the total area under the plasma concentration-time curve.

1 reference

12 December 2020

Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group.

1 reference

12 December 2020

Relationship between fluorouracil systemic exposure and tumor response and patient survival

1 reference

12 December 2020

Influence of sex and age on fluorouracil clearance

1 reference

12 December 2020

5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer

1 reference

12 December 2020

Plasma pharmacokinetics of 5-FU given by continuous infusion with allopurinol

1 reference

12 December 2020

Development and validation of a limited sampling strategy for 5-fluorouracil given by bolus intravenous administration

1 reference

12 December 2020

Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes

1 reference

12 December 2020

Is intra-arterial chemotherapy worthwhile in the treatment of patients with unresectable hepatic colorectal cancer metastases?

1 reference

12 December 2020

Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey

1 reference

12 December 2020

‘Tomudex’ (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia

1 reference

12 December 2020

Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer

1 reference

12 December 2020

Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs

1 reference

12 December 2020

Population study of dihydropyrimidine dehydrogenase in cancer patients

1 reference

12 December 2020

Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU

1 reference

12 December 2020

Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics

1 reference

12 December 2020

The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases

1 reference

12 December 2020

Different intravenous administration techniques for 5-fluorouracil. Pharmacokinetics and pharmacodynamic effects.

1 reference

12 December 2020

Clearance of continuously infused 5-fluorouracil in adults having lung or gastrointestinal carcinoma with or without hepatic metastases

1 reference

12 December 2020

Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer

1 reference

12 December 2020

Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients

1 reference

12 December 2020

Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer

1 reference

12 December 2020

10.2165/00003088-199936060-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

1023885149

0 references

1 reference